Kymera Therapeutics, Inc. 10-Q

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds. See “Use of Proceeds from Public Offering of Common Stock”. Use of Proceeds from Public Offering of Common Stock On August 20, 2020, our Registration Statement on Form S-1 (File No. 333-240264) relating to our initial public offering was declared effective by the Securities and Exchange Commission. On August 25, 2020, we issued and sold an aggregate of 9,987,520 shares of common stock, including the exercise in full by the underwriters of their option to purchase up to 1,302,720 additional shares of common stock, at a public offering price of $20.00 per share. The aggregate gross proceeds to the Company from the offering, before deducting underwriting discounts and commissions, and other estimated offering expenses payable by the Company, were approximately $199.8 million. All of the shares in the offering were sold by the Company. Morgan Stanley & Co. LLC, BofA Securities, Inc. and Cowen and Company, LLC were the representatives of the underwriters. There has been no material change in the planned use of proceeds from our initial public offering from that described in our final prospectus filed pursuant to Rule 424(b)(4) under the Securities Act with the SEC on August 21, 2020. 74 Concurrently with the initial public offering, the Company announced the concurrent sale of 676,354 common shares at the public offering price per share in a private placement to Vertex Pharmaceuticals Incorporated. The sale of these common shares was not registered under the Securities Act of 1933, as amended. Th e aggregate gross proceeds to the Company from the concurrent private placement, before deducting expenses payable by the Company, were approximately $13.5 million. The concurrent private placement also closed on August 25, 2020. Item 3. Defaults Upon Senior Securities. None. Item 4. Mine Safety Disclosures. None.